Trial to Test If Intermittent Fasting Can Boost Prostate Cancer Treatment Efficacy
/in Clinical Trial, Localized, Metastatic, Phase 1, Phase 2/by MaxKCL-HO-1i: A Novel HO-1 Inhibitor Targeting Tumor-Associated Macrophages
/in Preclinical Research/by MaxNewsletter 32/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week’s newsletter is more concise, spotlighting clinical trials over preclinical research. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. For more details on […]
New Bacterial Therapy Destroys Tumors in Immunocompromised Animal Models
/in Oncolytic, Preclinical Research/by MaxPhase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC)
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC
/in Clinical Trial, Phase 1, Phase 2/by MaxFDA Clears First-in-Human Trial of NSD2 Inhibitor in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 30/2026 July 26, 2026
- Biallelic Loss in DDR Genes and Its Clinical Impact July 25, 2026
- How DNA “Switches” in Prostate Cancer May Open New Treatment Paths July 25, 2026
- UPDATE: VIR-5500 Extended into mHSPC July 24, 2026